Compare Amphastar Pharmaceuticals Inc (AMPH) vs Global X Uranium ETF (URA) Price & Performance

AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.

The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.

URA, the Global X Uranium ETF, trades at $45.63, up 2.82% with a bullish technical signal from moving averages. The ETF benefits from strong policy support including $17.5 billion in federal nuclear funding and growing AI power demand. Recent index additions like Terra Innovatum and Eagle Nuclear Energy expand exposure to nuclear supply chain companies. RSI_6 at 92.76 indicates potential short-term overbought conditions while ADX signals strong trend momentum.

The uranium sector outlook remains positive with nuclear energy positioned as a solution to AI power demands and global energy security needs. Key risks include ETF concentration in uranium miners and sensitivity to commodity price volatility. Support at $45 and resistance at $46 will be critical for near-term price direction as the sector capitalizes on nuclear renaissance tailwinds.